BNT327, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

Meanwhile, its clinical pipeline also includes CTLA-4-targeting Probody therapeutics BMS-986249 and BMS-986288 – developed in partnership with Bristol Myers Squibb – and CX-904, a ...

PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific ...

Overall, we believe RT-114 has the potential to fill the current gap in the obesity treatment landscape as a first-in-class oral bispecific GLP-1/GLP-2 receptor agonist. Our Phase 1 study of RT-114 is ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Treatment-related mortality was not significantly different between frail and non-frail patients. B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in ...

Phase 3 results Tarlatamab (Amgen) Bispecific delta-like ligand 3-directed CD3 T-cell engager Treatment of small cell lung cancer in patients who progressed on or after a single line of platinum-based ...

2373.HK Beauty Farm Medical and Health Industry Inc.